Get started
Author

Elise Bonnet

Observed name: E. Bonnet
ORCID: 0000-0002-7061-0993
Observed ORCID: 0000-0002-7061-0993
OpenAlex ID: A5053451637
Genomic alterations and radioresistance in breast cancer: an analysis of the ProfiLER protocol
2017 · E. Bernichon, A. Vallard, et al. · Annals of Oncology · 30
PDF
Maintenance olaparib after platinum-based chemotherapy for advanced/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial
2025 · Florence Joly, Alexandra Leary, et al. · Nature Communications · 14
PDF
Alterations in Homologous Recombination-Related Genes and Distinct Platinum Response in Metastatic Triple-Negative Breast Cancers: A Subgroup Analysis of the ProfiLER-01 Trial
2022 · Elise Bonnet, Véronique Haddad, et al. · Journal of Personalized Medicine · 13
PDF
FOLFIRINOX in Patients With Peritoneal Carcinomatosis From Pancreatic Adenocarcinoma: A Retrospective Study
2019 · E. Bonnet, C. Mastier, et al. · Current Oncology · 11
PDF
Improving real-world evaluation of patient- and physician-reported tolerability: niraparib for recurrent ovarian cancer (NiQoLe)
2024 · Florence Joly, Fernando Bazan, et al. · JNCI Cancer Spectrum · 5
PDF
Pure Seminoma and Concurrent Aggressive Lymphoma: Case Report of a Patient With Persistent Müllerian Duct Syndrome
2018 · Elise Bonnet, Sophie Tartas, et al. · Clinical Genitourinary Cancer · 4
PDF
ESR1 Mutation in Endocrine Treatment-Naïve Endometrial Cancer: Prevalence, Characteristics, and Prognostic Implications, Results from the UTOLA Phase II GINECO Trial
2026 · Félix Blanc-Durand, Catherine Genestie, et al. · Clinical Cancer Research · 2
2022-RA-922-ESGO Histo-molecular characteristics of platinum-sensitive advanced endometrial cancer: data issued from the population included in the GINECO UTOLA study
2022 · Florence Joly, Pierre Alexandre Just, et al. · International Journal of Gynecological Cancer · 2
PDF
Characterization of Proficient Mismatch Repair Endometrial Cancer Subpopulation of the Randomized Phase Ii Gineco-utola Study
2026 · Francois Cherifi, Raphaël Leman, et al. · International Journal of Gynecological Cancer
Data from ESR1 Mutation in Endocrine Treatment-Naïve Endometrial Cancer: Prevalence, Characteristics, and Prognostic Implications, Results from the UTOLA Phase II GINECO Trial
2026 · Félix Blanc-Durand, Catherine Genestie, et al.
Supplementary Table S1 from ESR1 Mutation in Endocrine Treatment-Naïve Endometrial Cancer: Prevalence, Characteristics, and Prognostic Implications, Results from the UTOLA Phase II GINECO Trial
2026 · Félix Blanc-Durand, Catherine Genestie, et al.
Association between molecular classification and overall survival in patients with metastatic endometrial carcinoma: ancillary results of the UTOLA phase II GINECO trial
2025 · Guillaume Beinse, Karen Leroy, et al. · International Journal of Gynecological Cancer
1159P Validation of transcriptome profiling for prognostication of metastatic endometrial carcinoma beyond p53 molecular subgroup: Ancillary results from the UTOLA GINECO trial
2025 · G. Beinse, A. Kime, et al. · Annals of Oncology
1133P GREAT: Clinical outcomes from a prospective study of 1,456 patients (pts) with advanced ovarian cancer (AOC), including theranostic biomarker analysis (BRCA and genomic instability score) and paired tumor/DNA collection in the PARP inhibitor era
2025 · T. De La Motte Rouge, L. Deiana, et al. · Annals of Oncology
Characterization Of The PMMR Advanced Endometrial Cancer Subpopulation Of The Randomized Phase II GINECO-UTOLA Study
2025 · François Cherifi, Raphael Leman, et al. · International Journal of Gynecological Cancer
41MO ESR1 mutation in untreated endometrial cancer: Prevalence, characteristics and prognostic implications from the UTOLA trial
2024 · F. Blanc-Durand, S. Nikolaev, et al. · ESMO Open
PDF
Works count: 16
Citation count: 81
H-index: 5
I10-index: 4
Year
Topic
Type